Nanobiotix Sa ADR (NBTX)
NASDAQ:NBTX
NBTX Stock Chart & Stats
$32.65
-$0.03(-1.02%)
At close: 4:00 PM EST
$32.65
-$0.03(-1.02%)
Day’s Range― - ―
52-Week Range$2.99 - $41.89
Previous CloseN/A
Volume23.08K
Average Volume (3M)54.49K
Market Cap
$1.43B
Enterprise Value$1.25B
Total Cash (Recent Filing)$28.82M
Total Debt (Recent Filing)$51.24M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Apr 28, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,401,120
10 Day Avg. Volume68,014
30 Day Avg. Volume54,494
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-1.99
Price to Sales (P/S)-11.28
P/FCF Ratio-6.42
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue217.99
Enterprise Value/Gross Profit217.99
Enterprise Value/Ebitda-36.81
Forecast
1Y Price Target
$26.00Price Target Upside-20.37% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$42.83M
Bulls Say, Bears Say
Bulls Say
Strategic PartnershipThe $71 million agreement with HealthCare Royalty provides non-dilutive funding, extending cash runway into 2028, supporting long-term growth and development of cancer treatments.
Clinical Development ProgressBy transferring trial control to J&J, Nanobiotix enhances development and scalability of NBTXR3, potentially expanding its market presence in oncology.
Promising Clinical ResultsPositive Phase 1 results for NBTXR3 in esophageal cancer could open new treatment indications, strengthening Nanobiotix's market position in oncology.
Bears Say
Financial InstabilityPersistent negative equity and high leverage indicate financial distress, limiting Nanobiotix's ability to invest in growth and sustain operations long-term.
Negative Cash FlowsOngoing negative cash flows strain liquidity, hindering Nanobiotix's ability to fund operations and R&D without external financing.
Revenue DeclineSignificant revenue decline reflects operational challenges and impacts Nanobiotix's capacity to achieve profitability and sustain business growth.
Nanobiotix News
NBTX FAQ
What was Nanobiotix Sa ADR’s price range in the past 12 months?
Nanobiotix Sa ADR lowest stock price was $2.98 and its highest was $41.89 in the past 12 months.
What is Nanobiotix Sa ADR’s market cap?
Nanobiotix Sa ADR’s market cap is $1.43B.
When is Nanobiotix Sa ADR’s upcoming earnings report date?
Nanobiotix Sa ADR’s upcoming earnings report date is Apr 28, 2026 which is in 34 days.
How were Nanobiotix Sa ADR’s earnings last quarter?
Currently, no data Available
Is Nanobiotix Sa ADR overvalued?
According to Wall Street analysts Nanobiotix Sa ADR’s price is currently Overvalued.
Does Nanobiotix Sa ADR pay dividends?
Nanobiotix Sa ADR does not currently pay dividends.
What is Nanobiotix Sa ADR’s EPS estimate?
Nanobiotix Sa ADR’s EPS estimate is 0.3.
How many shares outstanding does Nanobiotix Sa ADR have?
Nanobiotix Sa ADR has 48,401,120 shares outstanding.
What happened to Nanobiotix Sa ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix Sa ADR?
Currently, no hedge funds are holding shares in NBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanobiotix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.00 (-20.37% Downside)
$26.00 (-20.37% Downside)
Blogger Sentiment
Bullish
NBTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 105.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.5%
Last 30 Days ▲ 14.8%
Last 30 Days ▲ 14.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
702.35%
12-Months-Change
Fundamentals
Return on Equity
76.70%
Trailing 12-Months
Asset Growth
-42.92%
Trailing 12-Months
Company Description
Nanobiotix Sa ADR
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
NBTX Stock 12 Month Forecast
Average Price Target
$26.00
▼(-20.37% Downside)
Technical Analysis
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
11.62% Other Institutional Investors
88.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---